Drug delivery systems for treatment of infections
AssigneeWayne State University
InventorsArun K. Iyer, Samaresh Sau, Michael Rybak, Ketki Bhise, Razie Kebriaei
Life of this patent
Estimating the term…
Abstract
Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the FIG. 5 treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.
Claims63
A method of treating Staphylococcus (S.) aureus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a liposomal nanoparticle comprising:
- a lipid component comprising a 1:0.5:0.07 ratio of HSPC to cholesterol to DSPE-mPEG, or a 1:0.05:0.007:0.007 ratio of HSPC to cholesterol to DSPE-mPEG to DSPE-PEG-Folate;
- or a 1:0.5:0.07 ratio of DOTAP to cholesterol to DSPE-mPEG;
- at least 10% vancomycin;
- and
- cefazolin, thereby treating S. aureus infection in the subject.
A method of treating Staphylococcus (S.) aureus infection in a subject in need thereof, comprising administering a therapeutically effective amount of a drug delivery system comprising vancomycin and cefazolin to the subject thereby treating S. aureus infection in the subject.
A method of reducing the nephrotoxicity associated with therapeutic vancomycin administration to a subject, the method comprising administering a preparation comprising a therapeutically effective amount of a lipid nanoparticle comprising vancomycin and cefazolin to the subject thereby reducing the nephrotoxicity associated with therapeutic vancomycin administration in the subject.
A lipid nanoparticle or drug delivery system comprising at least 10% vancomycin.
A modified water in oil (reverse phase) evaporation method for making a liposome nanoparticle with high vancomycin loading, the method comprising:
- dissolving in a 1:1 mixture of diethyl ether:
- chloroform:
- HSPC:
- cholesterol:
- DSPE-mPEG in a 1:0.5:0.07 ratio (w/w), or
- HSPC:
- cholesterol:
- DSPE-mPEG:
- DSPE-PEG-Folate in a 1:0.05:0.007:0.007 ratio (w/w), or
- DOTAP:
- cholesterol:
- DSPE-mPEG in a 1:0.5:0.07 ratio (w/w);
- evaporating the organic phase to obtain a thin film of lipid mixture;
- re-dissolving the resulting thin film in the same organic phase at the same ratio and adding an equal volume of sterile PBS to form an emulsion;
- breaking the emulsion by high energy cavitation produced using a sonicator;
- evaporating the organic phase to obtain a clear liposomal solution;
- separating unencapsulated vancomycin from the clear liposomal solution by gel column filtration;
- and
- size-extruding at 60° C. through 200 nm and 100 nm membranes.
A method of forming a nanoparticle disclosed herein utilizing water in oil emulsion, reverse phase evaporation.
Use of an antibiotic chemically conjugated with a lipid molecule as an active component of a therapeutic liposome, to improve the stability and long circulation of the antibiotic, substantially as described herein.
Liposomes in the hydrophilic core of which are captured one or more oligomicelles (OMs) comprising at least one conjugated or encapsulated antibiotic, substantially as described herein.
Dependencies are inferred from the claim text.